Globally, there are 589 million people with diabetes, causing 3.4 million deaths annually. The diabetes drug market reached nearly $80 billion in 2025 and is projected to exceed $153.4 billion by 2033. This chart shows the changes in market share of existing diabetes drugs, illustrating the growing trend of small-molecule drugs, with PS001 being a representative of this new class of drugs, aligning with current trends in diabetes treatment.

Early to mid-stage patients primarily use small-molecule drugs, accounting for 55% of the existing diabetes drug market, while DPP4 inhibitors and GLP1 analogs are newer areas with continuously growing market shares, currently representing 30% of the entire diabetes drug market; late-stage patients mainly use insulin and its derivatives, occupying 45% of the diabetes drug market. Our focus is on this 30% segment of the DPP4 inhibitor and GLP1 analog market.